Stevens-Johnson Syndrome Induced by Vandetanib.
10.5021/ad.2011.23.S3.S343
- Author:
Jimi YOON
1
;
Chee Won OH
;
Chi Yeon KIM
Author Information
1. Department of Dermatology, Institute of Health Science, School of Medicine, Gyeongsang National University, Jinju, Korea. dr_chiny@hotmail.com
- Publication Type:Case Report
- Keywords:
Non-small-cell lung carcinoma;
Stevens-Johnson syndrome;
Vandetanib
- MeSH:
Carcinoma, Non-Small-Cell Lung;
Cell Proliferation;
Diarrhea;
Hypertension;
Piperidines;
Protein-Tyrosine Kinases;
Quinazolines;
Receptor, Epidermal Growth Factor;
Receptors, Vascular Endothelial Growth Factor;
Stevens-Johnson Syndrome
- From:Annals of Dermatology
2011;23(Suppl 3):S343-S345
- CountryRepublic of Korea
- Language:English
-
Abstract:
Vandetanib is a once-daily oral anticancer drug that selectively inhibits key signaling pathways in cancer by targeting vascular endothelial growth factor receptors, epidermal growth factor receptors tyrosine kinase, and rearranged during transfection-dependent tumor cell proliferation and survival. The most frequently reported adverse events attributed to vandetanib include diarrhea, elevated aminotransferase, asymptomatic corrected QT interval prolongation, and hypertension. Though a number of randomized, doubleblind studies, including cutaneous adverse events attributed to vandetanib, have been reported along with these general symptoms, no case of Stevens-Johnson syndrome (SJS) has been reported. This paper demonstrates a case of SJS induced by vandetanib.
